HC Wainwright reiterated their buy rating on shares of XOMA (NASDAQ:XOMA – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $74.00 price objective on the biotechnology company’s stock.
Separately, StockNews.com raised XOMA to a sell rating in a research report on Wednesday, August 16th.
XOMA Price Performance
Institutional Trading of XOMA
Several hedge funds and other institutional investors have recently modified their holdings of XOMA. UBS Group AG lifted its position in shares of XOMA by 9,318.8% in the third quarter. UBS Group AG now owns 1,507 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 1,491 shares in the last quarter. Barclays PLC acquired a new position in shares of XOMA in the second quarter worth $28,000. BNP Paribas Arbitrage SNC acquired a new position in shares of XOMA in the second quarter worth $36,000. Bank of America Corp DE increased its stake in shares of XOMA by 40.7% in the fourth quarter. Bank of America Corp DE now owns 2,380 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 689 shares during the last quarter. Finally, California State Teachers Retirement System acquired a new position in shares of XOMA in the second quarter worth $46,000. Institutional investors and hedge funds own 65.35% of the company’s stock.
XOMA Corporation operates as a biotech royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.
- Five stocks we like better than XOMA
- 10 Best Airline Stocks to Buy
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- How to Buy Cheap Stocks Step by Step
- MarketBeat Week in Review – 9/11 – 9/15
- What is Put Option Volume?
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.